Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients

"\[Group 1\] Group A receives 100 PAU at week 1 and 200 PAU at week 2 as the induction phase.~200 PAU is administered for 3 to 16 weeks as a maintenance phase.~Group B (placebo group) is the placebo arm of group A.~\[Group 2\] As the induction phase, group C received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, and 400 PAU at week 4.~As the maintenance phase, 400 PAU is administered for 5 to 16 weeks.~Group D (placebo) is the placebo group in Group C.~\[Group 3\] As the induction phase, group E received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, 400 PAU at week 4, 600 PAU at week 5, and 800 PAU at week 6.~As the maintenance phase, 800 PAU is administered from 7 to 16 weeks.~Group F (placebo) is the placebo arm of group E."